There is an enormous and growing need for an alternative solution to the long waiting lists for organ transplantation and better human-relevant drug testing models. The production of artificial organs for transplantation would solve these issues of high demand and low availability, as well as post-surgical complications associated with organ rejection.
Bioprinting has the potential to revolutionize technology that will eventually make medical care rapid, inexpensive, to be conducted in a high-throughput manner, and oriented more towards personalization. For pharmaceutical development, 3D bioprinting offers a means of testing drugs more efficiently at a lower cost and with better biological relevance to humans than animal testing.
The 3D bioprinting market is projected to grow at a CAGR of 15.5% during the period 2022-2028 with a current (2022) holding valuation of US$ 2 billion. With incremental advances in 3D bioprinting expected over the next decade, the impact on the future of medicine could be transformational.